• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (Lomoparan), a low molecular weight heparinoid, in healthy volunteers.

作者信息

de Boer A, Stiekema J C, Danhof M, Breimer D D

机构信息

Center for Bio-Pharmaceutical Sciences, University of Leiden, The Netherlands.

出版信息

J Clin Pharmacol. 1991 Jul;31(7):611-7. doi: 10.1002/j.1552-4604.1991.tb03746.x.

DOI:10.1002/j.1552-4604.1991.tb03746.x
PMID:1716644
Abstract

The influence of chlorthalidone (100 mg PO) on the pharmacokinetics and pharmacodynamics of Org 10172 (IV bolus injection of 3250 anti-Xa units), a low molecular weight heparinoid, was studied in six healthy male volunteers using an open randomized two-way crossover design. Chlorthalidone produced a slight decrease in clearance of anti-Xa activity from 7.1 +/- 1.0 to 6.6 +/- 0.8 mL/min and a decrease of the volume of distribution from 0.20 +/- 0.05 to 0.16 +/- 0.04 L/kg, whereas the volume of distribution of antithrombin activity increased from 0.14 +/- 0.05 to 0.26 +/- 0.10 L/kg (all differences P less than .05). During the entire study period no adverse events occurred. In summary, chlorthalidone showed separate effects on different fractions of Org 10172. The clinical implication of the slight change observed in plasma anti-Xa activity is likely to be limited, whereas the 80% increase in distribution volume of plasma antithrombin activity can not be defined as yet in terms of clinical relevance.

摘要

相似文献

1
Influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (Lomoparan), a low molecular weight heparinoid, in healthy volunteers.
J Clin Pharmacol. 1991 Jul;31(7):611-7. doi: 10.1002/j.1552-4604.1991.tb03746.x.
2
Interaction of the combined medication with the new low-molecular-weight heparinoid Lomoparan (Org 10172) and acenocoumarol.
Haemostasis. 1990;20(3):136-46. doi: 10.1159/000216120.
3
Interaction of ORG 10172, a low molecular weight heparinoid, and digoxin in healthy volunteers.
Eur J Clin Pharmacol. 1991;41(3):245-50. doi: 10.1007/BF00315437.
4
The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172.低分子量类肝素Org 10172对安替比林代谢的影响以及酶诱导对Org 10172反应的作用。
Br J Clin Pharmacol. 1991 Jul;32(1):23-9. doi: 10.1111/j.1365-2125.1991.tb05608.x.
5
Pharmacokinetic considerations on Orgaran (Org 10172) therapy.关于奥加兰(Org 10172)治疗的药代动力学考量
Haemostasis. 1992;22(2):73-84. doi: 10.1159/000216298.
6
Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.给予健康老年志愿者低分子量类肝素Org 10172的安全性和药代动力学。
Br J Clin Pharmacol. 1989 Jan;27(1):39-48. doi: 10.1111/j.1365-2125.1989.tb05333.x.
7
Interaction study between Org 10172, a low molecular weight heparinoid, and acetylsalicylic acid in healthy male volunteers.低分子量类肝素Org 10172与乙酰水杨酸在健康男性志愿者中的相互作用研究。
Thromb Haemost. 1991 Aug 1;66(2):202-7.
8
Studies of interaction of a low-molecular-weight heparinoid (Org 10172) with cloxacillin and ticarcillin in healthy male volunteers.低分子量类肝素(Org 10172)与氯唑西林和替卡西林在健康男性志愿者体内相互作用的研究。
Antimicrob Agents Chemother. 1991 Oct;35(10):2110-5. doi: 10.1128/AAC.35.10.2110.
9
ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man.ORG 10172:一种低分子量类肝素抗凝剂,在人体内半衰期较长。
Br J Clin Pharmacol. 1987 Jun;23(6):667-75. doi: 10.1111/j.1365-2125.1987.tb03100.x.
10
Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients.一种低分子肝素类似物(Org 10172)对健康志愿者和血液透析患者的抗凝作用。
Thromb Res. 1985 Jul 15;39(2):211-22. doi: 10.1016/0049-3848(85)90109-4.

引用本文的文献

1
Danaparoid: a review of its use in thromboembolic and coagulation disorders.达那肝素:关于其在血栓栓塞和凝血障碍中应用的综述
Drugs. 2002;62(15):2283-314. doi: 10.2165/00003495-200262150-00016.
2
Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.达那肝素。其药理学及在肝素诱导的血小板减少症管理中的临床应用综述。
Drugs. 1997 Dec;54(6):903-24. doi: 10.2165/00003495-199754060-00008.